Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator.

Abstract

Zuranolone (SAGE-217) is a novel, synthetic, clinical stage neuroactive steroid GABAA receptor positive allosteric modulator designed with the pharmacokinetic properties to support oral daily dosing. In vitro, zuranolone enhanced GABAA receptor current at nine unique human recombinant receptor subtypes, including representative receptors for both synaptic (γ subunit-containing) and extrasynaptic (δ subunit-containing) configurations. At a representative synaptic subunit configuration, α1β2γ2, zuranolone potentiated GABA currents synergistically with the benzodiazepine diazepam, consistent with the non-competitive activity and distinct binding sites of the two classes of compounds at synaptic receptors. In a brain slice preparation, zuranolone produced a sustained increase in GABA currents consistent with metabotropic trafficking of GABAA receptors to the cell surface. In vivo, zuranolone exhibited potent activity, indicating its ability to modulate GABAA receptors in the central nervous system after oral dosing by protecting against chemo-convulsant seizures in a mouse model and enhancing electroencephalogram β-frequency power in rats. Together, these data establish zuranolone as a potent and efficacious neuroactive steroid GABAA receptor positive allosteric modulator with drug-like properties and CNS exposure in preclinical models. Recent clinical data support the therapeutic promise of neuroactive steroid GABAA receptor positive modulators for treating mood disorders; brexanolone is the first therapeutic approved specifically for the treatment of postpartum depression. Zuranolone is currently under clinical investigation for the treatment of major depressive episodes in major depressive disorder, postpartum depression, and bipolar depression.

• Authors: Alison L Althaus, Michael A Ackley, Gabriel M Belfort, Steven M Gee, Jing Dai, David P Nguyen, Tatiana M Kazdoba, Amit Modgil, Paul A Davies, Stephen J Moss, Francesco G Salituro, Ethan Hoffmann, Rebecca S Hammond, Albert J Robichaud, Michael C Quirk, James J Doherty
• Journal: Neuropharmacology (Neuropharmacology) Vol. 181 Pg. 108333 (12 15 2020) ISSN: 1873-7064 [Electronic] England
• PMID: 32976892 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Anticonvulsants
• Antidepressive Agents
• GABA Modulators
• GABA-A Receptor Agonists
• Pregnanes
• Pyrazoles
• Receptors, GABA
• Steroids
• gamma-Aminobutyric Acid
• zuranolone
• Diazepam

Topics

• Animals
• Anticonvulsants (pharmacokinetics, pharmacology)
• Antidepressive Agents (pharmacology)
• Binding Sites (drug effects)
• Brain (drug effects, metabolism)
• Diazepam (pharmacology)
• Drug Synergism
• Electroencephalography (drug effects)
• GABA Modulators (pharmacology)
• GABA-A Receptor Agonists (pharmacology)
• Hippocampus (drug effects)
• Humans
• Male
• Mice
• Pregnanes (pharmacokinetics, pharmacology)
• Pyrazoles (pharmacokinetics, pharmacology)
• Rats, Sprague-Dawley
• Receptors, GABA (drug effects)
• Seizures (chemically induced, prevention & control)
• Steroids (pharmacology)
• gamma-Aminobutyric Acid (physiology)